CN Patent

CN101616677A — 含脂质的制品

Assigned to Alnylam Pharmaceuticals Inc · Expires 2009-12-30 · 16y expired

What this patent protects

本发明描述了用于施予基于核酸的治疗剂的组合物和方法，所述组合物例如缔合复合物，如脂质体和脂质复合物(lipoplexes)。

USPTO Abstract

本发明描述了用于施予基于核酸的治疗剂的组合物和方法，所述组合物例如缔合复合物，如脂质体和脂质复合物(lipoplexes)。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: CN101616677A
Jurisdiction: CN
Classification: —
Expires: 2009-12-30
Drug substance claim: No
Drug product claim: No
Assignee: Alnylam Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.